These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 28601657)
1. Significance of positive and inhibitory regulators in the TGF-β signaling pathway in colorectal cancers. Coates RF; Gardner JA; Gao Y; Cortright VM; Mitchell JM; Ashikaga T; Skelly J; Yang MX Hum Pathol; 2017 Aug; 66():34-39. PubMed ID: 28601657 [TBL] [Abstract][Full Text] [Related]
2. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma. Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906 [TBL] [Abstract][Full Text] [Related]
4. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer. Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512 [TBL] [Abstract][Full Text] [Related]
5. High expression of COUP-TF II cooperated with negative Smad4 expression predicts poor prognosis in patients with colorectal cancer. Wang C; Zhou Y; Ruan R; Zheng M; Han W; Liao L Int J Clin Exp Pathol; 2015; 8(6):7112-21. PubMed ID: 26261604 [TBL] [Abstract][Full Text] [Related]
7. Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway. Geng J; Fan J; Ouyang Q; Zhang X; Zhang X; Yu J; Xu Z; Li Q; Yao X; Liu X; Zheng J Oncotarget; 2014 Jul; 5(14):5700-11. PubMed ID: 25026293 [TBL] [Abstract][Full Text] [Related]
8. Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma. Ahadi M; Andrici J; Sioson L; Sheen A; Clarkson A; Gill AJ Hum Pathol; 2016 Nov; 57():91-97. PubMed ID: 27476040 [TBL] [Abstract][Full Text] [Related]
9. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival. Singhi AD; Foxwell TJ; Nason K; Cressman KL; McGrath KM; Sun W; Bahary N; Zeh HJ; Levy RM; Luketich JD; Davison JM Am J Surg Pathol; 2015 Apr; 39(4):487-95. PubMed ID: 25634752 [TBL] [Abstract][Full Text] [Related]
10. Antimetastatic role of Smad4 signaling in colorectal cancer. Zhang B; Halder SK; Kashikar ND; Cho YJ; Datta A; Gorden DL; Datta PK Gastroenterology; 2010 Mar; 138(3):969-80.e1-3. PubMed ID: 19909744 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of stromal GREM1 expression in colorectal cancer. Jang BG; Kim HS; Chang WY; Bae JM; Oh HJ; Wen X; Jeong S; Cho NY; Kim WH; Kang GH Hum Pathol; 2017 Apr; 62():56-65. PubMed ID: 28041973 [TBL] [Abstract][Full Text] [Related]
12. SMAD4/DPC4 expression and prognosis in human colorectal cancer. Isaksson-Mettävainio M; Palmqvist R; Forssell J; Stenling R; Oberg A Anticancer Res; 2006; 26(1B):507-10. PubMed ID: 16739311 [TBL] [Abstract][Full Text] [Related]
13. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer. Gulubova M; Manolova I; Ananiev J; Julianov A; Yovchev Y; Peeva K Int J Colorectal Dis; 2010 May; 25(5):591-9. PubMed ID: 20165854 [TBL] [Abstract][Full Text] [Related]
14. Tumoral epithelial and stromal expression of SMAD proteins in pancreatic ductal adenocarcinomas. Handra-Luca A; Hammel P; Sauvanet A; Ruszniewski P; Couvelard A J Hepatobiliary Pancreat Sci; 2013 Mar; 20(3):294-302. PubMed ID: 22581056 [TBL] [Abstract][Full Text] [Related]
15. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Fleming NI; Jorissen RN; Mouradov D; Christie M; Sakthianandeswaren A; Palmieri M; Day F; Li S; Tsui C; Lipton L; Desai J; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Zhu HJ; Mariadason JM; Burgess AW; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM Cancer Res; 2013 Jan; 73(2):725-35. PubMed ID: 23139211 [TBL] [Abstract][Full Text] [Related]
16. Expression of TGF-beta1, TbetaRII and Smad4 in colorectal carcinoma. Xu WQ; Jiang XC; Zheng L; Yu YY; Tang JM Exp Mol Pathol; 2007 Jun; 82(3):284-91. PubMed ID: 17289018 [TBL] [Abstract][Full Text] [Related]
18. Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway. Bae JM; Kim JH; Rhee YY; Cho NY; Kim TY; Kang GH World J Gastroenterol; 2015 Sep; 21(33):9749-57. PubMed ID: 26361422 [TBL] [Abstract][Full Text] [Related]
19. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677 [TBL] [Abstract][Full Text] [Related]
20. Low expression of transforming growth factor beta-1 in cancer tissue predicts a poor prognosis for patients with stage III rectal cancers. Chun HK; Jung KU; Choi YL; Hong HK; Kim SH; Yun SH; Kim HC; Lee WY; Cho YB Oncology; 2014; 86(3):159-69. PubMed ID: 24643220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]